{"id":354368,"date":"2025-08-28T12:02:04","date_gmt":"2025-08-28T12:02:04","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-cellectis-sa\/"},"modified":"2025-08-28T12:02:04","modified_gmt":"2025-08-28T12:02:04","slug":"how-to-buy-cellectis-sa","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/","title":{"rendered":"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-354368","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Cellectis S.A. (CLLS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu yenilik\u00e7i biyotek hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, b\u00fcy\u00fcme potansiyeli ve 2025 i\u00e7in ak\u0131ll\u0131 yat\u0131r\u0131m stratejilerini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Cellectis S.A. (CLLS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu yenilik\u00e7i biyotek hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, b\u00fcy\u00fcme potansiyeli ve 2025 i\u00e7in ak\u0131ll\u0131 yat\u0131r\u0131m stratejilerini ke\u015ffedin."},"intro":"Kansere tedavisinin gelece\u011fine ait bir par\u00e7aya sahip oldu\u011funuzu hayal edin. Cellectis sadece ba\u015fka bir biyotek \u015firketi de\u011fil\u2014kanser tedavisinde devrim yaratabilecek haz\u0131r CAR-T terapileri geli\u015ftiriyorlar. Hisseleri hem patlay\u0131c\u0131 b\u00fcy\u00fcme potansiyeli sunuyor hem de hayat kurtaran t\u0131bbi yenilikleri desteklemenin tatminini sa\u011fl\u0131yor.","intro_source":{"label":"Intro","type":"text","formatted_value":"Kansere tedavisinin gelece\u011fine ait bir par\u00e7aya sahip oldu\u011funuzu hayal edin. Cellectis sadece ba\u015fka bir biyotek \u015firketi de\u011fil\u2014kanser tedavisinde devrim yaratabilecek haz\u0131r CAR-T terapileri geli\u015ftiriyorlar. Hisseleri hem patlay\u0131c\u0131 b\u00fcy\u00fcme potansiyeli sunuyor hem de hayat kurtaran t\u0131bbi yenilikleri desteklemenin tatminini sa\u011fl\u0131yor."},"body_html":"<h2>\ud83d\udcc8 Cellectis Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>28 A\u011fustos 2025 itibar\u0131yla, Cellectis S.A. (CLLS) NASDAQ borsas\u0131nda <strong>2,59 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Ancak as\u0131l \u00f6nemli olan \u015fu: <strong>3 Kas\u0131m 2025<\/strong> bir d\u00f6n\u00fcm noktas\u0131 olabilir. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 tarih bu ve ge\u00e7mi\u015f tecr\u00fcbeler tekrarlan\u0131rsa, \u00f6nemli fiyat hareketleri g\u00f6rebiliriz.<\/p> <p><strong>3 Kas\u0131m Neden \u00d6nemli:<\/strong><br\/> 4 A\u011fustos 2025'teki son kazan\u00e7 raporu, 2024 1. \u00e7eyre\u011findeki 6,5 milyon dolardan 12 milyon dolara gelirlerin iki kat\u0131na \u00e7\u0131kt\u0131\u011f\u0131n\u0131 g\u00f6sterdi. Hisse senedi duyurudan sonra ilk ba\u015fta hafif\u00e7e d\u00fc\u015ft\u00fc ancak yat\u0131r\u0131mc\u0131lar g\u00fc\u00e7l\u00fc 246 milyon dolarl\u0131k nakit pozisyonunu ve yakla\u015fan klinik tetikleyicileri sindirince h\u0131zla toparland\u0131.<\/p> <p><strong>Son Kazan\u00e7lar\u0131n Etki Deseni:<\/strong><\/p> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>\u00d6nceki Fiyat<\/th><th>Sonraki Fiyat<\/th><th>De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>4 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>2,70 $<\/td><td>2,65 $<\/td><td>-%1,9<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>1,84 $<\/td><td>2,15 $<\/td><td>+%16,8<\/td><\/tr> <tr><td>Mar 2025<\/td><td>2024 Mali Y\u0131l\u0131 Sonu\u00e7lar\u0131<\/td><td>1,50 $<\/td><td>1,75 $<\/td><td>+%16,7<\/td><\/tr> <\/tbody> <\/table> <p>Desen, yat\u0131r\u0131mc\u0131lar\u0131n klinik ilerlemeleri sindirmesiyle \u00f6nce volatilite ard\u0131ndan s\u00fcrd\u00fcr\u00fclebilir kazan\u00e7lar oldu\u011funu g\u00f6steriyor.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: M\u00fccadeleden Y\u00fckseli\u015fe<\/h2> <p>Cellectis tam bir h\u0131z treni ya\u015fad\u0131! Son alt\u0131 ayda hisse senedi etkileyici bir <strong>%87,5 getiri<\/strong> sa\u011flad\u0131 ve ayn\u0131 d\u00f6nemde S&P 500'\u00fcn +%11 getirisini dramatik \u015fekilde geride b\u0131rakt\u0131.<\/p> <p><strong>Ayl\u0131k Da\u011f\u0131l\u0131m:<\/strong><\/p> <ul> <li><strong>Mart 2025<\/strong>: 1,50 $ (kazan\u00e7 sonras\u0131 momentum)<\/li> <li><strong>Nisan 2025<\/strong>: 1,75 $ (DS\u00d6 isimlendirme onay\u0131 art\u0131\u015f\u0131)<\/li> <li><strong>May\u0131s 2025<\/strong>: 2,15 $ (1. \u00e7eyrek kazan\u00e7 s\u00fcrprizi)<\/li> <li><strong>Haziran 2025<\/strong>: 2,40 $ (FDA toplant\u0131s\u0131 beklentisi)<\/li> <li><strong>Temmuz 2025<\/strong>: 2,65 $ (ba\u015far\u0131l\u0131 FDA\/EMA toplant\u0131lar\u0131)<\/li> <li><strong>A\u011fustos 2025<\/strong>: 2,59 $ (mevcut konsolidasyon)<\/li> <\/ul> <p>Hisse senedi 2025 ba\u015f\u0131nda 1,10 $ ile 52 haftan\u0131n en d\u00fc\u015f\u00fck seviyesine ula\u015ft\u0131 ve o zamandan beri 3,24 $ ile 52 haftan\u0131n en y\u00fcksek seviyesine do\u011fru y\u00fckseldi; bu da dipten %195'lik ola\u011fan\u00fcst\u00fc bir toparlanmay\u0131 temsil ediyor.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p><strong>K\u0131sa Vadeli (2025)<\/strong>: 3 Kas\u0131m kazan\u00e7lar\u0131 \u00e7evresinde volatilite bekleniyor, ancak teknik analizler 2. faz deneme ba\u015flang\u0131c\u0131n\u0131n do\u011frulamas\u0131yla y\u0131l sonuna kadar <strong>3,50-4,00 $<\/strong> aral\u0131\u011f\u0131na hareket potansiyeli g\u00f6steriyor.<\/p> <p><strong>2026 Tahmini<\/strong>: 2. faz verileri ve potansiyel ortakl\u0131k geni\u015flemeleriyle, klinik sonu\u00e7lar olumlu kal\u0131rsa CLLS <strong>6-8 $ aral\u0131\u011f\u0131na<\/strong> ula\u015fabilir.<\/p> <p><strong>2028 Projeksiyonu<\/strong>: Lasme-cel d\u00fczenleyici onay ve ticari ba\u015far\u0131 elde ederse, hisse senedi <strong>12-15 $ aral\u0131\u011f\u0131nda<\/strong> i\u015flem g\u00f6rebilir, zirve sat\u0131\u015f tahminlerine dayanarak.<\/p> <p><strong>2030 Vizyonu<\/strong>: Uzun vadeli modeller, g\u00fc\u00e7l\u00fc uygulama s\u00fcrerse mevcut seviyelerden %530 potansiyel getiriyle <strong>16,30 $ hedefi<\/strong> \u00f6ng\u00f6r\u00fcyor.<\/p> <p><strong>Sonu\u00e7<\/strong>: 3-5 y\u0131ll\u0131k ufku olan risk toleransl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in AL. Klinik tetikleyiciler ve ortakl\u0131k gelirleri ba\u015far\u0131 i\u00e7in birden fazla yol sunuyor.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <p><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/strong><\/p> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Biyotek hisseleri klinik verilere ba\u011fl\u0131d\u0131r\u2014olumsuz sonu\u00e7lar kazan\u00e7lar\u0131 h\u0131zla silebilir<\/li> <li><strong>Nakit Yak\u0131m\u0131<\/strong>: Gelir art\u0131\u015f\u0131na ra\u011fmen \u00e7eyreklik 18 milyon dolarl\u0131k zarar s\u00fcrd\u00fcr\u00fclebilirlik endi\u015feleri yarat\u0131yor<\/li> <li><strong>D\u00fczenleyici Engeller<\/strong>: FDA onaylar\u0131 asla garanti de\u011fildir, \u00f6zellikle yenilik\u00e7i terapiler i\u00e7in<\/li> <li><strong>Volatilite<\/strong>: %14,35 g\u00fcnl\u00fck volatilite mide buland\u0131ran fiyat dalgalanmalar\u0131 anlam\u0131na gelir<\/li> <li><strong>Ortakl\u0131k Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: Gelirin %57'si AstraZeneca'dan geliyor, bu da konsantrasyon riski yarat\u0131yor<\/li> <\/ul> <p><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/strong><\/p> <ul> <li>\u2705 Temmuz 2025'te FDA\/EMA toplant\u0131lar\u0131 ba\u015far\u0131yla tamamland\u0131<\/li> <li>\u2705 2025 ikinci yar\u0131s\u0131nda 2. faz deneme ba\u015flang\u0131c\u0131 bekleniyor<\/li> <li>\u2705 2027'ye kadar 246 milyon dolar nakit rezervi<\/li> <li>\u2705 AstraZeneca ortakl\u0131\u011f\u0131 istikrarl\u0131 gelir sa\u011fl\u0131yor<\/li> <li>\u2705 DS\u00d6 resmi isimlendirmesi d\u00fczenleyici ilerlemeyi do\u011fruluyor<\/li> <li>\u2705 16 Ekim 2025 Yat\u0131r\u0131mc\u0131 Ar-Ge G\u00fcn\u00fc b\u00fcy\u00fck bir tetikleyici olabilir<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 CLLS gibi y\u00fcksek riskli biyotek hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: Zamanlama riskini azaltmak i\u00e7in toplu de\u011fil par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li> <li><strong>3 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7lar hisse d\u00fc\u015ferse daha iyi giri\u015f noktas\u0131 sa\u011flayabilir<\/li> <li><strong>Klinik Tetikleyicileri Takip Edin<\/strong>: Ekim Ar-Ge G\u00fcn\u00fc ve 2. faz ba\u015flang\u0131c\u0131 \u00f6nemli olaylar<\/li> <li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: \"Biyotek hisseleriyle ticaret kalp ameliyat\u0131 yapmak gibidir\u2014i\u015fe yararsa heyecan verici, yaramazsa felaket. Belki \u00f6nce ka\u011f\u0131t \u00fczerinde pratik yap\u0131n!\"<\/li> <\/ol>  <h2>\u2705 Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ listeli hisseleri ve makul \u00fccretleri sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Kaybetmeye raz\u0131 oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"CLLS\" Aray\u0131n<\/td><td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Limit Emri Verin<\/td><td>Piyasa emirlerinden ka\u00e7\u0131n\u0131n\u2014maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td><\/tr> <tr><td>5<\/td><td>Emir Detaylar\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td><td>Komisyon \u00fccretleri ve takas tarihlerini kontrol edin<\/td><\/tr> <tr><td>6<\/td><td>Al\u0131m\u0131 Ger\u00e7ekle\u015ftirin<\/td><td>Onaylay\u0131n ve pozisyonunuzu takip edin<\/td><\/tr> <tr><td>7<\/td><td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td><td>3,24 $ (52 haftan\u0131n en y\u00fcksek seviyesi) gibi \u00f6nemli seviyeleri takip edin<\/td><\/tr> <tr><td>8<\/td><td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td><td>K\u00e2r alma ve zarar durdurma seviyelerini \u00f6nceden belirleyin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, borsaya giri\u015fin daha az korkutucu olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> - Ger\u00e7ek para ile stratejileri \u00f6nemli finansal taahh\u00fct olmadan test edebilirsiniz<\/li> <li><strong>\u015eim\u015fek H\u0131z\u0131nda Do\u011frulama<\/strong> - Herhangi bir resmi kimlik y\u00fckleyin ve dakikalar i\u00e7inde ticarete ba\u015flay\u0131n, g\u00fcnler de\u011fil<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong> - Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100'den fazla y\u00f6ntemle karlar\u0131n\u0131za eri\u015fin<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, CLLS gibi pozisyonlar\u0131 takip etmeyi kolayla\u015ft\u0131r\u0131rken, d\u00fc\u015f\u00fck giri\u015f engeli biyotek hisseleriyle pratik deneyim kazanman\u0131z\u0131 sa\u011flar ve portf\u00f6y\u00fcn\u00fcz\u00fc a\u015f\u0131r\u0131 riskten korur.<\/p>  <h2>\ud83c\udf0d 2025'te Cellectis: Gen D\u00fczenleme \u00d6nc\u00fcs\u00fc<\/h2> <p>Cellectis, TALEN\u00ae gen d\u00fczenleme teknoloji platformuyla t\u0131bbi yenili\u011fin \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirket, her hasta i\u00e7in \u00f6zel \u00fcretim gerektirmeyen, temelde \"haz\u0131r\" kanser tedavileri olan allojenik CAR-T terapileri geli\u015ftiriyor.<\/p> <p><strong>Mevcut Pazar Konumu<\/strong>: 300'den fazla verilmi\u015f patent ve b\u00fcy\u00fck ila\u00e7 \u015firketleriyle stratejik ortakl\u0131klarla Cellectis, teknolojisi etraf\u0131nda g\u00fc\u00e7l\u00fc bir fikri m\u00fclkiyet kalkan\u0131 olu\u015fturdu.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc, Nisan 2025'te lider aday\u0131 UCART22 i\u00e7in \"lasmecabtagene timgedleucel\" ismini verdi\u2014ba\u015far\u0131l\u0131 ila\u00e7 onaylar\u0131ndan \u00f6nce gelen \u00f6nemli bir d\u00fczenleyici d\u00f6n\u00fcm noktas\u0131. Bu isimlendirme onay\u0131, k\u00fcresel sa\u011fl\u0131k otoritelerinin bu terapinin kanser tedavisinde potansiyel \u00f6nemini tan\u0131d\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Cellectis Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>28 A\u011fustos 2025 itibar\u0131yla, Cellectis S.A. (CLLS) NASDAQ borsas\u0131nda <strong>2,59 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Ancak as\u0131l \u00f6nemli olan \u015fu: <strong>3 Kas\u0131m 2025<\/strong> bir d\u00f6n\u00fcm noktas\u0131 olabilir. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 tarih bu ve ge\u00e7mi\u015f tecr\u00fcbeler tekrarlan\u0131rsa, \u00f6nemli fiyat hareketleri g\u00f6rebiliriz.<\/p>\n<p><strong>3 Kas\u0131m Neden \u00d6nemli:<\/strong><br \/> 4 A\u011fustos 2025&#8217;teki son kazan\u00e7 raporu, 2024 1. \u00e7eyre\u011findeki 6,5 milyon dolardan 12 milyon dolara gelirlerin iki kat\u0131na \u00e7\u0131kt\u0131\u011f\u0131n\u0131 g\u00f6sterdi. Hisse senedi duyurudan sonra ilk ba\u015fta hafif\u00e7e d\u00fc\u015ft\u00fc ancak yat\u0131r\u0131mc\u0131lar g\u00fc\u00e7l\u00fc 246 milyon dolarl\u0131k nakit pozisyonunu ve yakla\u015fan klinik tetikleyicileri sindirince h\u0131zla toparland\u0131.<\/p>\n<p><strong>Son Kazan\u00e7lar\u0131n Etki Deseni:<\/strong><\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>\u00d6nceki Fiyat<\/th>\n<th>Sonraki Fiyat<\/th>\n<th>De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>4 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>2,70 $<\/td>\n<td>2,65 $<\/td>\n<td>-%1,9<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>1,84 $<\/td>\n<td>2,15 $<\/td>\n<td>+%16,8<\/td>\n<\/tr>\n<tr>\n<td>Mar 2025<\/td>\n<td>2024 Mali Y\u0131l\u0131 Sonu\u00e7lar\u0131<\/td>\n<td>1,50 $<\/td>\n<td>1,75 $<\/td>\n<td>+%16,7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Desen, yat\u0131r\u0131mc\u0131lar\u0131n klinik ilerlemeleri sindirmesiyle \u00f6nce volatilite ard\u0131ndan s\u00fcrd\u00fcr\u00fclebilir kazan\u00e7lar oldu\u011funu g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: M\u00fccadeleden Y\u00fckseli\u015fe<\/h2>\n<p>Cellectis tam bir h\u0131z treni ya\u015fad\u0131! Son alt\u0131 ayda hisse senedi etkileyici bir <strong>%87,5 getiri<\/strong> sa\u011flad\u0131 ve ayn\u0131 d\u00f6nemde S&#038;P 500&#8217;\u00fcn +%11 getirisini dramatik \u015fekilde geride b\u0131rakt\u0131.<\/p>\n<p><strong>Ayl\u0131k Da\u011f\u0131l\u0131m:<\/strong><\/p>\n<ul>\n<li><strong>Mart 2025<\/strong>: 1,50 $ (kazan\u00e7 sonras\u0131 momentum)<\/li>\n<li><strong>Nisan 2025<\/strong>: 1,75 $ (DS\u00d6 isimlendirme onay\u0131 art\u0131\u015f\u0131)<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 2,15 $ (1. \u00e7eyrek kazan\u00e7 s\u00fcrprizi)<\/li>\n<li><strong>Haziran 2025<\/strong>: 2,40 $ (FDA toplant\u0131s\u0131 beklentisi)<\/li>\n<li><strong>Temmuz 2025<\/strong>: 2,65 $ (ba\u015far\u0131l\u0131 FDA\/EMA toplant\u0131lar\u0131)<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: 2,59 $ (mevcut konsolidasyon)<\/li>\n<\/ul>\n<p>Hisse senedi 2025 ba\u015f\u0131nda 1,10 $ ile 52 haftan\u0131n en d\u00fc\u015f\u00fck seviyesine ula\u015ft\u0131 ve o zamandan beri 3,24 $ ile 52 haftan\u0131n en y\u00fcksek seviyesine do\u011fru y\u00fckseldi; bu da dipten %195&#8217;lik ola\u011fan\u00fcst\u00fc bir toparlanmay\u0131 temsil ediyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p><strong>K\u0131sa Vadeli (2025)<\/strong>: 3 Kas\u0131m kazan\u00e7lar\u0131 \u00e7evresinde volatilite bekleniyor, ancak teknik analizler 2. faz deneme ba\u015flang\u0131c\u0131n\u0131n do\u011frulamas\u0131yla y\u0131l sonuna kadar <strong>3,50-4,00 $<\/strong> aral\u0131\u011f\u0131na hareket potansiyeli g\u00f6steriyor.<\/p>\n<p><strong>2026 Tahmini<\/strong>: 2. faz verileri ve potansiyel ortakl\u0131k geni\u015flemeleriyle, klinik sonu\u00e7lar olumlu kal\u0131rsa CLLS <strong>6-8 $ aral\u0131\u011f\u0131na<\/strong> ula\u015fabilir.<\/p>\n<p><strong>2028 Projeksiyonu<\/strong>: Lasme-cel d\u00fczenleyici onay ve ticari ba\u015far\u0131 elde ederse, hisse senedi <strong>12-15 $ aral\u0131\u011f\u0131nda<\/strong> i\u015flem g\u00f6rebilir, zirve sat\u0131\u015f tahminlerine dayanarak.<\/p>\n<p><strong>2030 Vizyonu<\/strong>: Uzun vadeli modeller, g\u00fc\u00e7l\u00fc uygulama s\u00fcrerse mevcut seviyelerden %530 potansiyel getiriyle <strong>16,30 $ hedefi<\/strong> \u00f6ng\u00f6r\u00fcyor.<\/p>\n<p><strong>Sonu\u00e7<\/strong>: 3-5 y\u0131ll\u0131k ufku olan risk toleransl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in AL. Klinik tetikleyiciler ve ortakl\u0131k gelirleri ba\u015far\u0131 i\u00e7in birden fazla yol sunuyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<p><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/strong><\/p>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Biyotek hisseleri klinik verilere ba\u011fl\u0131d\u0131r\u2014olumsuz sonu\u00e7lar kazan\u00e7lar\u0131 h\u0131zla silebilir<\/li>\n<li><strong>Nakit Yak\u0131m\u0131<\/strong>: Gelir art\u0131\u015f\u0131na ra\u011fmen \u00e7eyreklik 18 milyon dolarl\u0131k zarar s\u00fcrd\u00fcr\u00fclebilirlik endi\u015feleri yarat\u0131yor<\/li>\n<li><strong>D\u00fczenleyici Engeller<\/strong>: FDA onaylar\u0131 asla garanti de\u011fildir, \u00f6zellikle yenilik\u00e7i terapiler i\u00e7in<\/li>\n<li><strong>Volatilite<\/strong>: %14,35 g\u00fcnl\u00fck volatilite mide buland\u0131ran fiyat dalgalanmalar\u0131 anlam\u0131na gelir<\/li>\n<li><strong>Ortakl\u0131k Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: Gelirin %57&#8217;si AstraZeneca&#8217;dan geliyor, bu da konsantrasyon riski yarat\u0131yor<\/li>\n<\/ul>\n<p><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/strong><\/p>\n<ul>\n<li>\u2705 Temmuz 2025&#8217;te FDA\/EMA toplant\u0131lar\u0131 ba\u015far\u0131yla tamamland\u0131<\/li>\n<li>\u2705 2025 ikinci yar\u0131s\u0131nda 2. faz deneme ba\u015flang\u0131c\u0131 bekleniyor<\/li>\n<li>\u2705 2027&#8217;ye kadar 246 milyon dolar nakit rezervi<\/li>\n<li>\u2705 AstraZeneca ortakl\u0131\u011f\u0131 istikrarl\u0131 gelir sa\u011fl\u0131yor<\/li>\n<li>\u2705 DS\u00d6 resmi isimlendirmesi d\u00fczenleyici ilerlemeyi do\u011fruluyor<\/li>\n<li>\u2705 16 Ekim 2025 Yat\u0131r\u0131mc\u0131 Ar-Ge G\u00fcn\u00fc b\u00fcy\u00fck bir tetikleyici olabilir<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5&#8217;inden fazlas\u0131n\u0131 CLLS gibi y\u00fcksek riskli biyotek hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: Zamanlama riskini azaltmak i\u00e7in toplu de\u011fil par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>\n<li><strong>3 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7lar hisse d\u00fc\u015ferse daha iyi giri\u015f noktas\u0131 sa\u011flayabilir<\/li>\n<li><strong>Klinik Tetikleyicileri Takip Edin<\/strong>: Ekim Ar-Ge G\u00fcn\u00fc ve 2. faz ba\u015flang\u0131c\u0131 \u00f6nemli olaylar<\/li>\n<li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: &#8220;Biyotek hisseleriyle ticaret kalp ameliyat\u0131 yapmak gibidir\u2014i\u015fe yararsa heyecan verici, yaramazsa felaket. Belki \u00f6nce ka\u011f\u0131t \u00fczerinde pratik yap\u0131n!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeli hisseleri ve makul \u00fccretleri sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Kaybetmeye raz\u0131 oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;CLLS&#8221; Aray\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit Emri Verin<\/td>\n<td>Piyasa emirlerinden ka\u00e7\u0131n\u0131n\u2014maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Emir Detaylar\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td>\n<td>Komisyon \u00fccretleri ve takas tarihlerini kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Al\u0131m\u0131 Ger\u00e7ekle\u015ftirin<\/td>\n<td>Onaylay\u0131n ve pozisyonunuzu takip edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td>\n<td>3,24 $ (52 haftan\u0131n en y\u00fcksek seviyesi) gibi \u00f6nemli seviyeleri takip edin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td>\n<td>K\u00e2r alma ve zarar durdurma seviyelerini \u00f6nceden belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, borsaya giri\u015fin daha az korkutucu olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> &#8211; Ger\u00e7ek para ile stratejileri \u00f6nemli finansal taahh\u00fct olmadan test edebilirsiniz<\/li>\n<li><strong>\u015eim\u015fek H\u0131z\u0131nda Do\u011frulama<\/strong> &#8211; Herhangi bir resmi kimlik y\u00fckleyin ve dakikalar i\u00e7inde ticarete ba\u015flay\u0131n, g\u00fcnler de\u011fil<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong> &#8211; Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100&#8217;den fazla y\u00f6ntemle karlar\u0131n\u0131za eri\u015fin<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, CLLS gibi pozisyonlar\u0131 takip etmeyi kolayla\u015ft\u0131r\u0131rken, d\u00fc\u015f\u00fck giri\u015f engeli biyotek hisseleriyle pratik deneyim kazanman\u0131z\u0131 sa\u011flar ve portf\u00f6y\u00fcn\u00fcz\u00fc a\u015f\u0131r\u0131 riskten korur.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Cellectis: Gen D\u00fczenleme \u00d6nc\u00fcs\u00fc<\/h2>\n<p>Cellectis, TALEN\u00ae gen d\u00fczenleme teknoloji platformuyla t\u0131bbi yenili\u011fin \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirket, her hasta i\u00e7in \u00f6zel \u00fcretim gerektirmeyen, temelde &#8220;haz\u0131r&#8221; kanser tedavileri olan allojenik CAR-T terapileri geli\u015ftiriyor.<\/p>\n<p><strong>Mevcut Pazar Konumu<\/strong>: 300&#8217;den fazla verilmi\u015f patent ve b\u00fcy\u00fck ila\u00e7 \u015firketleriyle stratejik ortakl\u0131klarla Cellectis, teknolojisi etraf\u0131nda g\u00fc\u00e7l\u00fc bir fikri m\u00fclkiyet kalkan\u0131 olu\u015fturdu.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc, Nisan 2025&#8217;te lider aday\u0131 UCART22 i\u00e7in &#8220;lasmecabtagene timgedleucel&#8221; ismini verdi\u2014ba\u015far\u0131l\u0131 ila\u00e7 onaylar\u0131ndan \u00f6nce gelen \u00f6nemli bir d\u00fczenleyici d\u00f6n\u00fcm noktas\u0131. Bu isimlendirme onay\u0131, k\u00fcresel sa\u011fl\u0131k otoritelerinin bu terapinin kanser tedavisinde potansiyel \u00f6nemini tan\u0131d\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n"},"faq":[{"question":"Cellectis S.A. hisseleri nereden al\u0131nabilir?","answer":"Cellectis S.A. hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden CLLS sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Cellectis hisselerinin 2025 sonu fiyat tahmini nedir?","answer":"Teknik analizlere g\u00f6re, 2025 sonunda Cellectis hisseleri 3,50-4,00 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rebilir."},{"question":"Cellectis hisseleri i\u00e7in en \u00f6nemli riskler nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, y\u00fcksek nakit yak\u0131m\u0131, d\u00fczenleyici onay riskleri, y\u00fcksek volatilite ve AstraZeneca ortakl\u0131\u011f\u0131na ba\u011f\u0131ml\u0131l\u0131k ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayan biri Cellectis hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmay\u0131n, par\u00e7a par\u00e7a al\u0131m yap\u0131n, \u00f6nemli tarihleri takip edin ve risk y\u00f6netimi stratejileri uygulay\u0131n."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum yat\u0131r\u0131m tutar\u0131, h\u0131zl\u0131 do\u011frulama s\u00fcreci ve \u00e7ok \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ile Pocket Option, yeni ba\u015flayanlar\u0131n borsaya kolayca giri\u015f yapmas\u0131n\u0131 sa\u011flar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Cellectis S.A. hisseleri nereden al\u0131nabilir?","answer":"Cellectis S.A. hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden CLLS sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Cellectis hisselerinin 2025 sonu fiyat tahmini nedir?","answer":"Teknik analizlere g\u00f6re, 2025 sonunda Cellectis hisseleri 3,50-4,00 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rebilir."},{"question":"Cellectis hisseleri i\u00e7in en \u00f6nemli riskler nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, y\u00fcksek nakit yak\u0131m\u0131, d\u00fczenleyici onay riskleri, y\u00fcksek volatilite ve AstraZeneca ortakl\u0131\u011f\u0131na ba\u011f\u0131ml\u0131l\u0131k ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayan biri Cellectis hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmay\u0131n, par\u00e7a par\u00e7a al\u0131m yap\u0131n, \u00f6nemli tarihleri takip edin ve risk y\u00f6netimi stratejileri uygulay\u0131n."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum yat\u0131r\u0131m tutar\u0131, h\u0131zl\u0131 do\u011frulama s\u00fcreci ve \u00e7ok \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ile Pocket Option, yeni ba\u015flayanlar\u0131n borsaya kolayca giri\u015f yapmas\u0131n\u0131 sa\u011flar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T12:02:04+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-28T12:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/\",\"name\":\"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-28T12:02:04+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/","og_locale":"tr_TR","og_type":"article","og_title":"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-28T12:02:04+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-28T12:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/","name":"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-28T12:02:04+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cellectis-sa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Cellectis S.A. (CLLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cellectis S.A. (CLLS) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":354374,"slug":"how-to-buy-cellectis-sa","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Cellectis S.A. (CLLS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Cellectis S.A. (CLLS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-cellectis-sa\/"},"pt_AA":{"locale":"pt_AA","id":354372,"slug":"how-to-buy-cellectis-sa","post_title":"Como comprar a\u00e7\u00f5es da Cellectis S.A. (CLLS) - Investimento em a\u00e7\u00f5es da Cellectis S.A. (CLLS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-cellectis-sa\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/354368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=354368"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/354368\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=354368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=354368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=354368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}